6 news items
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
TAK
26 Apr 24
in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease
TAK
18 Apr 24
, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
TAK
27 Mar 24
are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
TAK
13 Mar 24
laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
TAK
26 Feb 24
pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product
p2a5bl
TAK
26 Feb 24
employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries
- Prev
- 1
- Next